Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353581 | 0.79 | MITF (0.46) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL3282371 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL19674728 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL13431485 | 0.76 | ALDH1A1 (0.75) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL18786131 | 0.75 | ALDH1A1 (0.50) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL18776142 | 0.75 | ALDH1A1 (0.42) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL15686430 | 0.75 | ALDH1A1 (0.42) | ALDH1A1SOS1PKMKMT2ALMNA | |
| SCHEMBL10747319 | 0.75 | ALDH1A1 (0.42) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL5331712 | 0.75 | ALDH1A1 (0.42) | ALDH1A1SOS1PKMPOLBKMT2A | |
| SCHEMBL27262043 | 0.75 | ALDH1A1 (0.54) | ALDH1A1SOS1PKMPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116120238-B | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116120238-A | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-116120238-B | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116120238-B | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116120238-A | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116120238-A | Preparation method of imidazole derivative | 山东梅奥华卫科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3362100-B1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-08-21 | — | — | US | disclosed |
| US-7368579-B2 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| EP-0072919-B1 | PROCESS FOR THE PREPARATION OF 1,2-DIMETHYL-5-NITROIMIDAZOLE OF HIGH PURITY | BASF Aktiengesellschaft (DE) | 1986-01-08 | — | — | EP | disclosed |
| EP-0072919-A1 | Process for the preparation of 1,2-dimethyl-5-nitroimidazole of high purity | BASF Aktiengesellschaft (DE) | 1983-03-02 | — | — | EP | disclosed |
| EP-0006463-B1 | PROCESS FOR THE PRODUCTION OF 2-SUBSTITUTED 1-ALKYL-NITROIMIDAZOLES | BASF Aktiengesellschaft (DE) | 1981-11-25 | — | — | EP | disclosed |
| US-4267349-A | Process for the preparation of 2-substituted-alkyl-1-alkyl-nitroimidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4232165-A | 2-Substituted-1-alkyl-nitroimidazoles | BASF AKTIENGESELLSCHAFT (DE) | 1980-11-04 | — | — | US | disclosed |
| EP-0006463-A1 | Process for the production of 2-substituted 1-alkyl-nitroimidazoles | BASF Aktiengesellschaft (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | ALDH1A1 836/4885SOS1 2129/4885PKM 1876/4885 |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | ALDH1A1 4561/4885SOS1 2499/4885PKM 1119/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | ALDH1A1 4561/4885SOS1 2499/4885PKM 1119/4885 |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | ALDH1A1 836/4885SOS1 2129/4885PKM 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.